Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Total Liabilities : $1.99 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Total Liabilities?

Shuttle Pharmaceuticals Holdings's Total Liabilities for the quarter that ended in Mar. 2024 was $1.99 Mil.

Shuttle Pharmaceuticals Holdings's quarterly Total Liabilities increased from Sep. 2023 ($1.77 Mil) to Dec. 2023 ($1.90 Mil) and increased from Dec. 2023 ($1.90 Mil) to Mar. 2024 ($1.99 Mil).

Shuttle Pharmaceuticals Holdings's annual Total Liabilities declined from Dec. 2021 ($2.28 Mil) to Dec. 2022 ($0.98 Mil) but then increased from Dec. 2022 ($0.98 Mil) to Dec. 2023 ($1.90 Mil).

Shuttle Pharmaceuticals Holdings Total Liabilities Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Total Liabilities Chart

Shuttle Pharmaceuticals Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Liabilities

2.23

2.28

0.98

1.90

Shuttle Pharmaceuticals Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial									3.53	1.90	1.77	1.90	1.99

Shuttle Pharmaceuticals Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shuttle Pharmaceuticals Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.042	+	(0.439	+	0.415
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.90

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5.952	-	4.056
	=	1.90

Shuttle Pharmaceuticals Holdings's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.489	+	(0.289	+	0.214
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.99

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	4.754	-	2.761
	=	1.99

Shuttle Pharmaceuticals Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Research Court, Suite 450, Rockville, MD, USA, 20850

Website

https://www.shuttlepharma.com

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Executives

Milton Brown	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo	officer: President and COO	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo	director, 10 percent owner, officer: CEO and Chairman	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich	officer: Chief Medical Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung	officer: Chief Scientific Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander	officer: Chief Financial Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850